

Resource Summary Report

Generated by [NIF](#) on Sep 16, 2026

COV362

RRID:CVCL_2420

Type: Cell Line

Proper Citation

RRID:CVCL_2420

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2420

Proper Citation: RRID:CVCL_2420

Description: Cell line COV362 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: [PMID:8436435](#), [PMID:22460905](#), [PMID:23839242](#), [PMID:25230021](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:32612269](#)

Comments: Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: OCCP ovarian cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: COV362

Synonyms: Cov362, COV-362

Cross References: EFO:EFO_0006383, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, BioGRID_ORCS_Cell_line:600, BioSample:SAMN03473268, BioSample:SAMN10987971, cancercellines:CVCL_2420, Cell_Model_Passport:SIDM01479, DepMap:ACH-000278, ECACC:07071910, EGA:EGAS00001000610, GEO:GSM886963, GEO:GSM888032, GEO:GSM1291135, IARC_TP53:28329, LiGeA:CCLE_216, PharmacDB:COV362_254_2019, Progenetix:CVCL_2420, Wikidata:Q54814342

ID: CVCL_2420

Record Creation Time: 20220427T215517+0000

Record Last Update: 20260913T002423+0000

Ratings and Alerts

No rating or validation information has been found for COV362.

No alerts have been found for COV362.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Kimura N, et al. (2026) CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy. Cancer research communications, 6(2), 383.

Pradhan B, et al. (2026) Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer. Cancer research, 86(4), 1073.

Santer FR, et al. (2026) Absence of synergistic effects by CDK12/13 inhibition in combination with cisplatin or olaparib in ovarian cancer cells. Scientific reports, 16(1).

Resch V, et al. (2026) Targeting Steroid-Metabolizing Enzymes with 15 β -Substituted Estrone Analogues: Dual Discovery of AKR1C2/17 β -HSD1 Inhibitors and a Fluorescent 17 β -HSD1 Ligand. Cancers, 18(12).

Gao Y, et al. (2026) DYRK1B Inhibition by AZ191 Sensitizes High-Grade Serous Ovarian Cancer to Niraparib Through Promoting Apoptosis and Ferroptosis. Biomedicines, 14(4).

Little S, et al. (2025) Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC. iScience, 28(6), 112555.

Bayraktar E, et al. (2025) Epigenetic modulation of BARD1 to enhance anti-VEGF therapy. Cell reports. Medicine, 6(9), 102329.

Gudoityte G, et al. (2025) Systematic profiling of cancer-fibroblast interactions reveals drug combinations in ovarian cancer. Molecular oncology, 19(9), 2574.

Kim D, et al. (2025) Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers. *NPJ precision oncology*, 9(1), 3.

Khetan R, et al. (2024) Unveiling G-protein coupled receptors as potential targets for ovarian cancer nanomedicines: from RNA sequencing data analysis to in vitro validation. *Journal of ovarian research*, 17(1), 156.

Dodson AE, et al. (2024) Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines. *Cancer research communications*, 4(12), 3084.

Tani T, et al. (2024) TREX1 Inactivation Unleashes Cancer Cell STING-Interferon Signaling and Promotes Antitumor Immunity. *Cancer discovery*, 14(5), 752.

Huang H, et al. (2023) N6-Methyladenosine RNA Modifications Regulate the Response to Platinum Through Nicotinamide N-methyltransferase. *Molecular cancer therapeutics*, 22(3), 393.

Li Y, et al. (2023) PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition. *Cell reports. Medicine*, 4(12), 101326.

Patel PS, et al. (2023) Excessive transcription-replication conflicts are a vulnerability of BRCA1-mutant cancers. *Nucleic acids research*, 51(9), 4341.

Liu H, et al. (2022) KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer. *Cancer immunology research*, 10(8), 1028.

Jia Y, et al. (2021) Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells. *Frontiers in oncology*, 11, 812264.

Handley KF, et al. (2021) Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. *Molecular cancer therapeutics*, 20(12), 2352.

Lin J, et al. (2021) The SETDB1-TRIM28 Complex Suppresses Antitumor Immunity. *Cancer immunology research*, 9(12), 1413.

Nachtigal MW, et al. (2021) Cytotoxic capacity of a novel glycosylated antitumor ether lipid in chemotherapy-resistant high grade serous ovarian cancer in vitro and in vivo. *Translational oncology*, 14(11), 101203.